Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Vismodegib, First Hedgehog Inhibitor, Approved for BCC Patients

January 30th 2012

The FDA has approved vismodegib for the treatment of patients with basal cell carcinoma.

Researchers Discover Basis for Secondary Skin Cancers in Patients Taking Vemurafenib

January 18th 2012

The molecular basis behind the relatively high incidence of secondary skin cancers after patients received vemurafenib has been discovered.

Dr. Cohen Discusses Hedgehog Pathway Inhibition

January 13th 2012

Dr. Deirdre Cohen, NYU Medical Oncology Associates, Discusses Hedgehog Pathway Inhibition

Study Supports Smaller Margins in Excising Thicker Melanomas

January 13th 2012

Patients with a primary cutaneous melanoma thicker than 2 mm can be safely treated with a 2-cm resection margin.

NICE's Reluctance to Back Yervoy Turns on Cost-Benefit Perceptions

January 12th 2012

NICE has issued a draft recommendation against Yervoy approval, stating it does not show benefits to justify its costs.

Hair Professionals Often Check Customers for Worrisome Skin Lesions

December 20th 2011

Some cosmetologists and barbers inspect their customers' scalps, necks, and faces for the presence of skin lesions that they think may be cancerous.

Dr. Mills Gives Examples of Unexpected Drug Responses

October 28th 2011

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses

Dr. Goy Highlights Recent Advances in Oncology

October 14th 2011

Dr. Andre Goy from John Theurer Cancer Center Highlights Recent Advances in Oncology

Novel Infusion Approach Significantly Delays Progression in Uveal Melanoma Patients With Liver Metastases

September 24th 2011

Patients with liver metastases from uveal melanoma had improved survival after treatment with percutaneous hepatic perfusion (PHP).

ASCO 2011: What Nurses Need to Know

August 26th 2011

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

ASCO Highlights: Trials in Progress

August 23rd 2011

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Dr. Hendrix on Metastatic Cells in Microenvironments

August 18th 2011

Dr. Mary J. C. Hendrix from Northwestern University's Feinberg School of Medicine on Metastatic Tumor Cells in Microenvironments

Vemurafenib Receives Approval for Metastatic Melanoma

August 17th 2011

The FDA approved vemurafenib and a companion diagnostic test in a move that was hailed as an advance for both patients and personalized medicine.

Dr. Hoos Discusses the Next Steps for Ipilimumab

August 9th 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab

Dr. Hoos Discusses Patients Eligible to Receive Ipilimumab

August 3rd 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab

Researchers Identify Gene Involved in DNA Repair From UVB Damage

July 29th 2011

The tumor suppressor gene PTEN has been linked to the removal of DNA damage from UVB radiation, a major risk factor in the development of skin cancer.

Dr. Hoos on the Ipilimumab Plus Dacarbazine Trial

July 29th 2011

Dr. Axel Hoos medical lead at bristol-myers squibb on the Ipilimumab Plus Dacarbazine Combination Trial

Flip Flops, Baseball Caps, and Skin Cancer

July 27th 2011

Sun exposure to usually-covered skin is yet another risk for skin cancer.

Dr. Hoos on Why Melanoma is Amenable to Immunotherapy

July 26th 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

BRIM-2 Upholds Benefits Emerging with Vemurafenib in Melanoma

July 25th 2011

In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates and durable treatment responses.